



THE HOUSE OF REPRESENTATIVES

STANDING COMMITTEE ON HEALTH

Inquiry into Hepatitis C in Australia

PUBLIC HEARING
Thursday 22 January 2015

Ionic Room
Sydney Masonic Centre, 66 Goulburn Street, Sydney

Roundtable

Time	Witness
9.00 am	<p><i>Briefing from the Department of Health and Therapeutic Goods Administration:</i></p> <p>Department of Health Mr Graeme Barden, Assistant Secretary, Health Protection Policy Branch Professor Chris Baggoley, Chief Medical Officer Dr Andrew Singer, Principal Medical Adviser, Acute Care Division</p> <p>Therapeutic Goods Administration Dr Anthony Hobbs, Principal Medical Adviser</p>

9.40 am	<p><i>Prevalence Rates, Testing and Treatment Options, and Related Costs (Terms of Reference (a), (b) and (c)):</i> Aboriginal Health and Medical Research Council of NSW Inc Ms Sandra Bailey, Chief Executive Officer Ms Bronwyn Briggs, Project Officer, Public Health Unit Ms Sallie Cairnduff, Manager, Public Health Unit Mr Rodger Williams, Chief Operations Officer</p> <p>Australasian Society for HIV Medicine Adjunct Associate Professor Levinia Crooks, Chief Executive Officer</p> <p>Australian Liver Association (part of the Gastroenterological Society of Australia) Professor Geoff McCaughan, Chair of the Transplant Society of Australia and New Zealand Professor Stuart Roberts, Chair of the Australian Liver Association Clinical Research Network Professor Amany Zekry, Chair of the Australian Liver Association</p> <p>Department of Health Mr Graeme Barden, Assistant Secretary, Health Protection Policy Branch Professor Chris Baggoley, Chief Medical Officer Dr Andrew Singer, Principal Medical Adviser, Acute Care Division</p> <p>Dr Mark Douglas, Senior Lecturer, Westmead Millennium Institute; Infectious Diseases and Hepatitis Specialist, Westmead Hospital</p> <p>Centre for Social Research in Health Professor John de Wit, Director</p> <p>Hepatitis NSW Mr Alastair Lawrie, Policy and Media Officer Mr Stuart Loveday, Chief Executive Officer</p> <p>Kirby Institute Professor Gregory Dore, Head, Viral Hepatitis Clinical Research Program Professor Lisa Maher, Program Head and NHMRC Senior Research Fellow</p> <p>National Aboriginal Community Controlled Health Organisation Ms Lisa Briggs, Chief Executive Officer</p> <p>Therapeutic Goods Administration Dr Anthony Hobbs, Principal Medical Adviser</p>
11.15 am	<i>Break</i>
11.30 am	<p><i>Prevention and Awareness (Terms of Reference (d)):</i> Same witnesses as for previous session</p>
1.00 pm	<i>Lunch break</i>
2.00 pm	<i>People living with hepatitis C (6 Witnesses)</i>
3.30 pm	<i>Close</i>